临床与病理杂志2017，Vol.37Issue(12)：2543-2548,6.DOI:10.3978/j.issn.2095-6959.2017.12.005
胰腺导管腺癌患者KRAS与SMAD4基因的突变情况
KRAS and SMAD4 gene mutations in patients with pancreatic ductal adenocarcinoma
李永星 1邢晓明 1李胜勇 2王丽丽 1李广起 1宋琳 3杨平4
作者信息
- 1. 青岛大学附属医院病理科,山东青岛266000
- 2. 威海市立医院病理科,山东威海264200
- 3. 山东省立医院病理科,济南250000
- 4. 毓璜顶医院病理科,山东烟台264006
- 折叠
摘要
Abstract
Objective:To investigate the mutations of KRAS and SMAD4 (DPC4) genes and to determine the relationship between the gene mutations and clinicopathological characteristics in patients with pancreatic ductal adenocarcinoma (PDAC) in Shandong Province.Methods:Fifty paraffin-embedded tissues from patients with PDAC without radiotherapy and chemotherapy were enrolled in this study.The KRAS gene exon 2 and the whole exons of SMAD4 gene were sequenced by Sanger sequencing.The relationship between mutations and clinicopathological features was analyzed.Results:The mutation rate ofKRAS gene exon 2 was 72％ (36/50),including 35 cases with mutations at codon 12 (p.Gly12Asp 23 cases,p.Gly12Arg 2 cases,p.Gly12Val 8 cases,p.Gly12Cys 2 cases),and 1 case with mutations at codon 6 c.16C＞T [p.(Leu6Phe)] and codon 23 (c.67C＞T).The KRAS mutations were associated with tumor stage (P＜0.01),poor differentiation (P＜0.05) and lymph node metastasis (P＜0.01).No mutation in the whole exons ofSMAD4 gene was detected in this study.Conclusion:The mutation of KRAS gene is significantly associated with malignancy and poor prognosis in patients with PDAC in Shandong Province.SMAD4 mutation is rarely detected in these patients,which indicates possible geographic discrepancy ofSMAD4 gene mutation.关键词
胰腺导管腺癌/SMAD4/DPC4/KRAS/突变Key words
pancreatic ductal adenocarcinoma/SMAD4/DPC4/KRAS/mutation引用本文复制引用
李永星,邢晓明,李胜勇,王丽丽,李广起,宋琳,杨平..胰腺导管腺癌患者KRAS与SMAD4基因的突变情况[J].临床与病理杂志,2017,37(12):2543-2548,6.
